Pricing Log in Create free account

Gyre Therapeutics, Inc. (GYRE) vs Monopar Therapeutics Inc. (MNPR)

Gyre Therapeutics, Inc. and Monopar Therapeutics Inc. are both Biotechnology companies. Gyre Therapeutics, Inc. and Monopar Therapeutics Inc. are of similar size ($451.2M and $425.2M). Monopar Therapeutics Inc. has the higher net margin (0.00% vs −21.5%) and the higher return on invested capital (0.00% vs −8.51%). Across the 11 metrics below, Monopar Therapeutics Inc. leads on 7 and Gyre Therapeutics, Inc. on 4.

Valuation

Metric GYRE MNPR Biotechnology median
P/E n/m n/m 10.60
P/S 4.12 n/m 9.40
P/B 3.47 4.66 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 3.55 n/m 9.02
Earnings yield (5.93%) (3.04%) (32.88%)
Free cash flow yield (5.07%) (2.00%) (23.13%)

Profitability

Metric GYRE MNPR Biotechnology median
Gross margin 91.71% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin (21.46%) 0.00% 0.00%
Free cash flow margin (19.94%) 0.00% 0.00%
Return on equity (18.54%) (19.50%) (51.96%)
Return on assets (14.49%) (18.90%) (46.06%)
Return on invested capital (8.51%) 0.00% 0.00%

Growth

Metric GYRE MNPR Biotechnology median
Revenue growth (TTM) 13.51% — 6.76%
EPS growth (last fiscal year) (60.00%) 54.99% 29.88%
Revenue growth, 5-year CAGR 40.96% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GYRE MNPR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.32 33.56 4.97
Net debt to EBITDA (3.74) 8.06 1.01

Dividend

Metric GYRE MNPR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GYRE MNPR Biotechnology median
Market cap 425.20m 451.19m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack